Desogestrel and Ethinyl estradiol is a combined oral contraceptive (COC) that contains two active ingredients: desogestrel, a progestin, and ethinyl estradiol, a synthetic estrogen. The medication is supplied as a tablet (pill) in a fixed-dose formulation of 0.15 mg desogestrel and 30 µg ethinyl estradiol. In Hong Kong, combined oral contraceptives are prescription-only medicines regulated by the Department of Health and the Medicines and Poisons Ordinance.
Combined oral contraceptives prevent pregnancy primarily by interfering with the normal ovarian cycle.
Onset of contraceptive effect occurs after the first tablet for most women, but a backup method (e.g., condoms) is recommended during the first seven days of use. The tablets are rapidly absorbed from the gastrointestinal tract, with an oral bioavailability of roughly 50 % for ethinyl estradiol and 70 % for desogestrel. Both agents are metabolised in the liver (primarily via CYP3A4) and excreted in urine and bile.
In Hong Kong, the approved indications for this combination pill are:
The medication is not indicated for the treatment of hormonal disorders unrelated to contraception (e.g., polycystic ovary syndrome) unless a physician determines a combined oral contraceptive is appropriate for symptom management.
Evidence from peer-reviewed studies indicates that combined oral contraceptives may provide secondary benefits such as:
These uses are off-label and are not approved by the Hong Kong Department of Health. Off-label use requires careful medical supervision, individualized risk assessment, and informed consent.
Mechanism: Most interactions involve the hepatic CYP3A4 pathway, altering plasma concentrations of either hormone.
Patients should disclose all prescription medicines, over-the-counter products, herbal supplements, and dietary habits to their prescriber.
Overdose: Symptoms may include nausea, vomiting, abdominal pain, and uterine bleeding. Seek emergency medical care; treatment is primarily supportive. Activated charcoal may be considered if ingestion is recent.
Discontinuation: No tapering is required. Menstrual cycles will typically return to baseline within 4-6 weeks after stopping.
If a patient develops signs of VTE, severe hypertension, or hepatic dysfunction, the medication should be stopped and appropriate medical management instituted.
This article provides educational information about Desogestrel and Ethinyl estradiol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
The effectiveness of the pill is maintained as long as it is taken once daily. Choosing a consistent time (e.g., every morning) helps establish a routine and reduces the chance of missed doses.
Severe or persistent headaches, especially if accompanied by visual disturbances, may signal a serious neurological event. Seek immediate medical evaluation to rule out migraine with aura or a possible vascular complication.
Most women experience a return to their natural menstrual pattern within 4-6 weeks after discontinuation. Some may notice a temporary delay or a brief period of irregular bleeding.
Yes, the pill remains effective across time zones. When crossing more than three time zones, try to maintain the same local time for dosing; if this is impossible, take the missed dose as soon as possible and continue the usual schedule.
Many manufacturers market generic versions of this combination with identical active ingredients and strengths. While inactive excipients may vary slightly, therapeutic effectiveness remains comparable.
Mild, well-controlled asthma is not a contraindication. However, if asthma is severe or associated with chronic inflammation, discuss any concerns with your healthcare provider.
Concurrent use is generally unnecessary; an IUD provides long-acting contraception, while the pill offers systemic hormonal effects. If both are prescribed, your physician will assess the need for combined therapy.
Long-term use of combined oral contraceptives has been associated with a slight, reversible increase in breast cancer risk. The absolute risk remains low, and the protective effect against ovarian and endometrial cancers may offset this risk for many women.
Moderate coffee consumption does not affect the efficacy or safety of the medication. Excessive caffeine intake may exacerbate headache or anxiety in susceptible individuals.
Do not flush tablets down the toilet. Return them to a pharmacy or community drug-take-back program to minimize environmental contamination.
